Celldex Therapeutics ( NASDAQ:CLDX ) has recently emerged as a frontrunner in this arena, unveiling compelling results from its innovative treatment for chronic hives. The consequential findings have ignited a surge in investor enthusiasm, propelling the biotech stock to its highest point since October 2021.
Celldex's ( NASDAQ:CLDX ) breakthrough revolves around...
